The FDA’s decision on Friday to approve a new blood thinner from Portola Pharmaceuticals has biotech investors optimistic that the agency, now under new management, will be easier to get along with than administrations past.

Portola’s drug, called Bevyxxa, overcame what could have been a damning clinical result — it failed to show statistically significant benefits over an old generic. It’s now approved to prevent blood clots in patients who’ve been hospitalized for medical illness but didn’t require surgery.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy